<SEC-DOCUMENT>0001213900-26-003668.txt : 20260113
<SEC-HEADER>0001213900-26-003668.hdr.sgml : 20260113
<ACCEPTANCE-DATETIME>20260113071031
ACCESSION NUMBER:		0001213900-26-003668
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20260113
FILED AS OF DATE:		20260113
DATE AS OF CHANGE:		20260113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		26528396

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0272536-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of January 2026 (Report No. 2)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: 001-38041</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCISPARC
LTD.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20
Raul Wallenberg Street, Tower A,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Tel
Aviv 6971916 Israel</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 20-F &#9746;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="text-align: left; padding-left: 0pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 40-F &#9744;</FONT></TD></TR>
</TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2026, SciSparc Ltd. (the &ldquo;Company&rdquo;) and Xylo Technologies Ltd. (&ldquo;Xylo&rdquo;) entered into an asset purchase
agreement (the &ldquo;Agreement&rdquo;) pursuant to which the Company agreed to acquire the complete portfolio of patents, trademarks,
know-how, brand names and related intellectual property rights, including unregistered intellectual property rights, owned by Xylo. In
consideration for these acquired assets, the Company agreed to issue to Xylo an amount of ordinary shares of the Company, which shall
represent as of the closing date, 19.99% of the issued and outstanding share capital of the Company (the &ldquo;Issued Shares&rdquo;).
The Company may elect at its sole discretion to issue, in lieu (in whole or in part) of the Issued Shares, pre-funded warrants to purchase
ordinary shares. The Agreement contains customary representations, warranties and covenants of the Company and Xylo, including the Company&rsquo;s
obligation to ensure that the Issued Shares shall represent 19.99% of the issued and outstanding share capital of the Company at the
closing and to file a registration statement with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) to register the
resale of the Issued Shares within 30 days from the Closing Date (as defined below). The closing of the transaction, which is expected
on March 8, 2026 (the &ldquo;Closing Date&rdquo;), will be subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Agreement set forth above is qualified in its entirety by reference to the full text of the Agreement attached
hereto as Exhibit 10.1 to this Report of Foreign Private Issuer on Form 6-K (this &ldquo;Report&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2026, the Company issued a press release titled &ldquo;SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents
for the Endoscope Market- Entering Multi-Billion Dollar Opportunity.&rdquo; A copy of this press release is furnished herewith as Exhibit
99.1 to this Report and is incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under
the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Report is incorporated by reference into the Company&rsquo;s registration statements on Form F-3 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000101376225002218/ea0235372-f3_scisparc.htm">333-286099</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023083494/ea187529-f3_scisparc.htm">333-275305</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm">333-269839</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm">333-266047</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm">333-248670</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023018886/ea174796-posam_scisparc.htm">333-255408</A>)
and on Form S-8 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390024028880/ea0203015-s8_scisparc.htm">333-278437</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390025035801/ea0239224-s8_scisparc.htm">333-286791</A>)
filed with the SEC to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cautionary
Note Regarding Forward-Looking Statements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Report contains forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation
Reform Act of 1995 and other Federal securities laws. For example, the Company uses forward-looking statements when it discusses: the
expected acquisition of a portfolio of patents, trademarks and intellectual property rights from Xylo; the Closing Date and the consideration
for the acquired assets to be paid to Xylo at closing. Because such statements deal with future events and are based on the Company&rsquo;s
current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company
could differ materially from those described in or implied by the statements in this Report. The forward-looking statements contained
or implied in this Report are subject to other risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo;
in the Company&rsquo;s Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the SEC.
Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
INDEX</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="ea027253602ex10-1_scisparc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset Purchase Agreement, dated January 8, 2026, by and between Xylo Technologies Ltd. and SciSparc Ltd.</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ea027253602ex99-1_scisparc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by SciSparc Ltd. titled &ldquo;SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SciSparc Ltd.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 13, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea027253602ex10-1_scisparc.htm
<DESCRIPTION>ASSET PURCHASE AGREEMENT, DATED JANUARY 8, 2026, BY AND BETWEEN XYLO TECHNOLOGIES LTD. AND SCISPARC LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-decoration: none"><B>ASSET
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">This
Asset Purchase Agreement (the &ldquo;</FONT>Agreement<FONT STYLE="font-weight: normal">&rdquo;), is made effective as of January 8, 2026
(the &ldquo;APA </FONT>Effective Date<FONT STYLE="font-weight: normal">&rdquo;), by and between:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">XYLO Technologies Ltd.<FONT STYLE="font-weight: normal">,
a private company organized under the laws of the State of Israel, company registration number 512866971, registered address at 10 Hanechoshet
St., Tel Aviv &ndash; Yafo 6971072, Israel (the &ldquo;</FONT>Seller<FONT STYLE="font-weight: normal">&rdquo;); and</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SciSparc Ltd.<FONT STYLE="font-weight: normal">,
a public company organized under the laws of the State of Israel, company registration number 513581652, registered address at 20 Raoul
Wallenberg St., Tel Aviv &ndash; Yaffo 6971904, Israel (the &ldquo;</FONT>Buyer<FONT STYLE="font-weight: normal">&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">W
I T N E S S E T H :</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1.25in">WHEREAS</TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">the
                                            Buyer desires to purchase and acquire from Seller, and the Seller desires to sell, assign
                                            and transfer to Buyer the Acquired Assets as existing on the Effective Date for the Transaction
                                            Consideration (as such terms are defined below), subject, in each case, to the exceptions,
                                            terms and conditions set forth herein.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">NOW, THEREFORE, <FONT STYLE="font-weight: normal">for
good and valuable consideration, the receipt and adequacy of which are acknowledged by each of the Seller and the Buyer, the parties
hereto, intending to be legally bound hereby, agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><B><U>PURCHASE
                                            AND SALE</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1.</TD><TD STYLE="text-align: justify"><U>Nature of the Transaction and Acquisition
                                            and Transfer of Acquired Assets</U>. Upon the terms and subject to the conditions hereinafter
                                            set forth, at the Closing (as such term is defined below) the Seller shall sell, assign,
                                            transfer, convey and deliver to the Buyer, and the Buyer shall purchase, acquire and accept
                                            from the Seller&nbsp;all right, title and interest in and to the Acquired Assets defined
                                            in this Section 1.1 below, as existing on the Effective Date. The Acquired Assets will be
                                            sold, assigned, transferred and conveyed to Buyer on the Closing Date (as defined below)
                                            on an &ldquo;<I>As Is</I>&rdquo;, &ldquo;<I>Where Is</I>&rdquo; and &ldquo;<I>As Available</I>&rdquo;
                                            basis, with no representations or warranties other than those specifically set forth below.
                                            At the Closing and subject to the issuance of the Issued Shares (as defined below), the Acquired
                                            Assets will be transferred and assigned to Buyer free and clear of all liens, encumbrances,
                                            and other third party rights (other than rights included in the Assumed Liabilities) (&ldquo;<B>Liens</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The term &ldquo;<B>Acquired
Assets</B>&rdquo; means:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Patent Rights listed on <B><U>Schedule
                                            1.1</U></B> (the&nbsp;&ldquo;<B>Transferred Patent Rights</B>&rdquo;), including all claims
                                            and causes of action with respect to any of the foregoing, whether past, present or future,
                                            including all rights to and claims for damages, restitution, and injunctive and other legal
                                            and equitable relief for infringement; &ldquo;<B>Patent Rights</B>&rdquo; means all patents
                                            and patent applications (including provisional applications), as well as all renewals, reissues,
                                            divisions, substitutions, continuations, continuations-in-part, extensions and reexaminations
                                            and all foreign counterparts thereof, registered or applied for anywhere in the world, together
                                            with all associated patent files.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Trademarks and brand names as specifically
                                            listed in each of <B><U>Schedule 1.1 (B)</U></B> (&ldquo;<B>Trademarks</B>&rdquo;) attached
                                            hereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">certain rights and obligations under
                                            agreements to which Seller is a party, as listed in <B><U>Schedule 1.1(C)</U></B> attached
                                            hereto (the &ldquo;<B>Assigned Contracts</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">unregistered intellectual property rights
                                            owned by Seller that are embodied within the Transferred Patent Rights and Trademarks (such
                                            as copyrights, trade secrets, use invention rights, past and future rights to sue for infringement),
                                            in each case, if and to the extent existing and related solely to the Transferred Patent
                                            Rights and Trademarks (together with the Transferred Patent Rights and Trademarks, collectively,
                                            the&nbsp;&ldquo;<B>Transferred IP Rights</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2.</TD><TD STYLE="text-align: justify"><U>Excluded Assets</U>. Buyer and Seller
                                            expressly understand and agree that the Acquired Assets will not include Seller&rsquo;s rights,
                                            title and assets in and to all other assets of the Seller not specifically listed or described
                                            in Section 1.1 above (collectively, the &ldquo;<B>Excluded Assets</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.3.</TD><TD STYLE="text-align: justify"><U>Assumed Liabilities</U>
                                            <FONT STYLE="font-weight: normal">On the terms and subject to the conditions set forth herein,
                                            Buyer shall assume and discharge or perform when due only those Liabilities arising out of
                                            or relating to the Acquired Assets from and after the signing of the binding term sheet,
                                            dated November 26, 2025 (&ldquo;</FONT><B>Effective Date</B><FONT STYLE="font-weight: normal">&rdquo;),
                                            including the use, ownership, possession, operation, sale or lease of the Acquired Assets
                                            (collectively, the&nbsp;&ldquo;</FONT><B>Assumed Liabilities</B><FONT STYLE="font-weight: normal">&rdquo;).
                                            </FONT>&ldquo;<B>Liabilities</B>&rdquo; <FONT STYLE="font-weight: normal">means any and all
                                            debts, liabilities, assessments, expenses, claims, losses, damages, deficiencies and obligations,
                                            whether accrued or fixed, known or unknown, absolute or contingent, matured or unmatured
                                            or determined or determinable including to the extent applicable liabilities towards the
                                            Israeli Innovation Authority related to the Acquired Assets.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.4.</TD><TD STYLE="text-align: justify"><U>Un-Assumed Liabilities</U>.
                                            As of the Effective Date, and except as specifically set forth in this Agreement, the Buyer
                                            shall not assume, pay, incur or in any way be liable or responsible for any of the Seller&rsquo;s
                                            debts, liabilities or obligations, which are not included in the Assumed Liabilities. It
                                            is agreed that to the extent applicable Seller shall assume the liability to the IIA with
                                            respect to the payment of the Transaction Consideration.</TD>
</TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD STYLE="text-align: justify"><B><U>TRANSACTION CONSIDERATION</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">In consideration for the sale, transfer, conveyance,
                                            and assignment of all of the Acquired Assets and Assumed Liabilities, the Buyer shall, subject
                                            to and upon the Closing, issue to the Seller an amount of ordinary shares, which shall represent
                                            as of the Closing Date, 19.99% of the issued and outstanding share capital of the Buyer (respectively,
                                            the &ldquo;<B>Transaction Consideration</B>&rdquo; and the &ldquo;<B>Issued Shares</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">The Buyer may elect at its sole discretion
                                            to issue, in lieu (in whole or in part) of the Issued Shares, prefunded warrants to purchase
                                            Ordinary Shares, in the form attached hereto as <B><U>Schedule B</U></B> (the &ldquo;<B>Warrant
                                            Shares</B>&rdquo; and &ldquo;<B>Warrant Certificate&rdquo;</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify">Registration
                                            Rights. Buyer shall prepare, and, as soon as practicable but in no event later than 30 days
                                            from the Closing Date, file with the Commission a registration statement on Form F-3 covering
                                            the resale of all of the Issued Shares (and/or if applicable Warrant Shares) (the &ldquo;<B>Filing
                                            Date</B>&rdquo;). In the event that Form F-3 is unavailable for such a registration, the
                                            Company shall use such other form as is available for such a registration on another appropriate
                                            form reasonably acceptable to the Seller. The Company shall use its reasonable best efforts
                                            to have the registration statement declared effective by the United States Securities and
                                            Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) as soon as practicable, but in
                                            no event later than the Effectiveness Deadline. &ldquo;<B>Effectiveness Deadline</B>&rdquo;
                                            means the date which is the earlier of (x) (i) in the event that the registration statement
                                            is not subject to a full review by the Commission, sixty (60) calendar days after the Filing
                                            Date or (ii) in the event that the registration statement is subject to a full review by
                                            the Commission or in the event that the Company is notified by the Commission to refile the
                                            registration statement on Form F-1, ninety (90) calendar days after the Filing Date and (y)
                                            the fifth (5th) Business Day after the date the Company is notified (orally or in writing,
                                            whichever is earlier) by the Commission that such registration statement will not be reviewed
                                            or will not be subject to further review; provided, however, that if the Effectiveness Deadline
                                            falls on a Saturday, Sunday or other day that the Commission is closed for business, the
                                            Effectiveness Deadline shall be extended to the next Business Day on which the Commission
                                            is open for business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify"><U>Taxes</U>. Each party shall bear and pay
                                            all of its own taxes according to applicable laws in connection with the performance of the
                                            transactions contemplated under this Agreement, including the issuance of the Issued Shares
                                            and/or the Warrant Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><B><U>CLOSING</U></B></FONT><B><U>
                                            &amp; CLOSING DELIVERABLES</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify"><U>Closing &amp; Closing Date</U>. Subject
                                            to the satisfaction of the conditions set forth in this Section 3 (or the waiver thereof
                                            by the party entitled to waive that condition), the closing shall take place by exchange
                                            of signed documentation on March 8, 2026 (the &ldquo;<B>Closing</B>&rdquo; and the &ldquo;<B>Closing
                                            Date</B>&rdquo;, respectively).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify"><U>Proceedings at Closing</U>. All proceedings
                                            taken, and all documents executed and delivered at the Closing shall be deemed to have been
                                            taken, executed and delivered simultaneously.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify"><U>Conditions to Obligations of each Party
                                            to effect the Agreement</U>. The respective obligations of each party to effect the transactions
                                            contemplated by this Agreement shall be subject to the satisfaction, at or prior to the Closing
                                            Date, of the following conditions:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.3.1</TD><TD STYLE="text-align: justify"><U>No Law or Order; Illegality</U>.
                                            No governmental entity shall have enacted, issued, promulgated, enforced or entered any law,
                                            order or other legal restraint (whether temporary, preliminary or permanent) which is in
                                            effect and which has the effect of making the transactions contemplated by this Agreement
                                            illegal or otherwise prohibiting or preventing consummation of the transactions contemplated
                                            by this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.3.2</TD><TD STYLE="text-align: justify"><U>Accuracy of Representations</U>.
                                            Each of the representations and warranties made by the parties in this Agreement shall have
                                            been true and correct in all material respects as of the APA Effective Date, and shall be
                                            true and correct in all material respects as of the Closing Date as if made on the Closing
                                            Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.3.3</TD><TD STYLE="text-align: justify"><U>No Injunctive Proceedings</U>.
                                            No preliminary or permanent injunction or other order (including a temporary restraining
                                            order) of any court or other governmental agency which prevents the consummation of the transactions
                                            which are the subject of this Agreement or prohibits Buyer&rsquo;s ownership of the Acquired
                                            Assets shall have been issued and remain in effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4</TD><TD STYLE="text-align: justify"><U>Documents to be delivered by the Seller
                                            at Closing</U>. At the Closing, the Seller shall deliver, or cause to be delivered, to the
                                            Buyer the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.4.1</TD><TD STYLE="text-align: justify">A bill of sale substantially in the
                                            form attached hereto as <B><U>Schedule 3.4.1</U></B>, dated on the Closing Date according
                                            to which the Seller shall transfer to Buyer the Transferred IP Rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.4.2</TD><TD STYLE="text-align: justify">Copies of all necessary corporate
                                            resolutions adopted by the Seller authorizing the execution of this Agreement and the sale
                                            of the Acquired Assets to the Buyer in accordance with the terms hereof in the form attached
                                            hereto as <B><U>Schedule 3.4.2</U></B>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.4.3</TD><TD STYLE="text-align: justify">Assignment Documents for the due assignment
                                            of the Transferred IP Rights, in the forms attached hereto as <B><U>Schedule 3.4.3(i)</U></B>
                                            <I>(patents)</I> and <B><U>Schedule 3.4.3(ii)</U></B> <I>(Trademarks).</I></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.4.4</TD><TD STYLE="text-align: justify">Seller obtained the consent of the
                                            parties of the Assigned Contracts for the assignment, in the form to be attached as <B><U>Schedule
                                            3.4.4</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.4.5</TD><TD STYLE="text-align: justify">a certificate executed by a duly authorized
                                            signatory of Seller, dated as of the Closing, certifying that each of the conditions set
                                            forth in Section 4 (Representations, Warranties and Covenants of Seller) has been satisfied.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.5</TD><TD STYLE="text-align: justify"><U>Documents to be delivered by the Buyer
                                            at Closing</U>. At the Closing Date, the Buyer shall deliver, or cause to be delivered, to
                                            the Seller the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.5.1</TD><TD STYLE="text-align: justify">the applicable restricted book entry
                                            statement representing the Issued Shares in the name of the Seller and/or the Pre-Funded
                                            Warrants.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.5.2</TD><TD STYLE="text-align: justify">Copies of all necessary corporate
                                            resolutions on part of the Buyer authorizing the execution of this Agreement, the purchase
                                            of the Acquired Assets by the Buyer and issuance of the Issued Shares and/or the Warrant
                                            Shares in accordance with the terms thereof in the form attached hereto as <B><U>Schedule
                                            3.5.2</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">3.5.3</TD><TD STYLE="text-align: justify">a certificate executed by a duly authorized
                                            signatory of Buyer, dated as of the Closing, certifying that each of the conditions set forth
                                            in Section 5 (Representations, Warranties and Covenants of Buyer) has been satisfied.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD STYLE="text-align: justify"><B><U>REPRESENTATIONS AND WARRANTIES
                                            OF THE SELLER</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Acquired Assets will be purchased
by Buyer with no representations or warranties, express or implied, by Seller, other than the following specific representations and
warranties which Seller hereby represents and warrants to Buyer that will be true and correct as of date hereof and as of the Closing
Date:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify"><U>Corporate Organization</U>. The Seller
                                            is a corporation duly organized and validly existing under the laws of the State of Israel
                                            and has all requisite corporate power and authority to execute, deliver and perform each
                                            of the Seller Documents (as defined below) and to consummate the transactions contemplated
                                            thereby.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify"><U>Power &amp; Authority; and no Default Upon
                                            Transfer</U>. The Seller has full corporate power and authority to execute and deliver this
                                            Agreement, and each other agreement, document, instrument or certificate which it shall deliver
                                            to the Buyer at the signing of the Agreement and at the Closing (this Agreement and all of
                                            such other agreements, documents, instruments and certificates shall be collectively referred
                                            to herein as the &ldquo;<B>Seller Documents</B>&rdquo;), and to perform fully its obligations
                                            under each of the Seller Documents. The execution, delivery and performance by the Seller
                                            of each of the Seller Documents have been duly authorized by all necessary corporate action
                                            on the part of the Seller. No other approvals are required in order to consummate the transactions
                                            contemplated by any of the Seller Documents (except for any such approval which has heretofore
                                            been duly obtained and continues to be in full force and effect). This Agreement has been,
                                            and each of the other Seller Documents has been or will at or prior to the Closing be, duly
                                            executed and delivered by the Seller and (assuming the due authorization, execution and delivery
                                            by the other parties thereto) each of the Seller Documents constitutes (or, when executed,
                                            will constitute) a legal, valid and binding obligation of the Seller, enforceable against
                                            the Seller in accordance with its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.3</TD><TD STYLE="text-align: justify"><U>Title to Acquired Assets</U>. Seller has,
                                            and at the Closing will transfer and deliver to the Buyer, good and valid title to all of
                                            the Acquired Assets free and clear of all Liens.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.4</TD><TD STYLE="text-align: justify">To the knowledge of Seller, all maintenance
                                            and annual fees that are due and payable have been fully paid, and all fees paid during prosecution
                                            and after issuance of any patent due and payable have been paid in the correct amounts, in
                                            each case with respect to the Transferred Patent Rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.5</TD><TD STYLE="text-align: justify"><U>Assigned Contracts</U>. Neither Seller
                                            nor any other party to the Assigned Contracts, is in material breach of or default under
                                            any of such contracts.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.6</TD><TD STYLE="text-align: justify"><U>Litigation</U>. There are no actions, suits,
                                            proceedings or governmental investigations pending or, to Seller&rsquo;s actual knowledge,
                                            threatened against Seller, before any court, governmental department, commission, board,
                                            agency, authority or instrumentality, domestic or foreign, that might affect in any way any
                                            of the Acquired Assets. To the Seller&rsquo;s knowledge, there are no judgments, decrees,
                                            injunctions or orders of any court, governmental body, department, commission, agency, instrumentality
                                            or arbitrator against Seller affecting the assignment of the Acquired Assets.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.7</TD><TD STYLE="text-align: justify"><U>Consents</U>. No consent, permit, waiver,
                                            approval, or authorization of, or declaration or filing with, or notification to, any person
                                            or governmental body is required on the part of the Seller in connection with the execution
                                            and delivery by the Seller of any of the Seller Documents. Notwithstanding the above, for
                                            the compliance by the Seller with any of the provisions hereof, including, without limitation,
                                            the assignment of any Acquired Assets contemplated by this Agreement, the Seller shall assist
                                            the Buyer with such assignment and transfer of any of the above as is required post-Closing.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.8</TD><TD STYLE="text-align: justify"><U>No Other Representations or Warranties</U>.
                                            Except for the representations and warranties expressly contained in this &lrm;Section &lrm;4,
                                            the Seller does not make any other express or implied representation or warranty.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD STYLE="text-align: justify"><B><U>REPRESENTATIONS AND WARRANTIES
                                            OF THE BUYER</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Buyer hereby represents and warrants
to the Seller as of date hereof and as of the Closing Date as follows:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify"><U>Corporate Organization</U>. The Buyer is
                                            a corporation duly organized and validly existing under the laws of the State of Israel and
                                            has all requisite corporate power and authority to execute, deliver and perform each of the
                                            Buyer Documents (as defined below) and to consummate the transactions contemplated thereby;
                                            to own, lease and operate its properties and other assets and to carry on its business as
                                            now being conducted. The Buyer is duly qualified or licensed to do business and is in good
                                            standing in each jurisdiction in which the nature of its business or the ownership or leasing
                                            of its properties makes such qualification or licensing necessary.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify"><U>Power &amp; Authority; and No Default</U>.
                                            The Buyer has full corporate power and authority to execute and deliver this Agreement and
                                            each other agreement, document, instrument or certificate which it shall deliver to the Seller
                                            at the signing of the Agreement and at the Closing (this Agreement and all of such other
                                            agreements, documents, instruments and certificates shall be collectively referred to herein
                                            as the &ldquo;<B>Buyer Documents</B>&rdquo;) and to perform fully its obligations under each
                                            of the Buyer Documents. The execution, delivery and performance by the Buyer of each of the
                                            Buyer Documents have been duly authorized by all necessary corporate action on the part of
                                            the Buyer. No other approvals are required in order to consummate the transactions contemplated
                                            by any of the Buyer Documents (except for any such approval which has heretofore been duly
                                            obtained and continues to be in full force and effect). This Agreement has been, and each
                                            of the other Buyer Documents has been or will at or prior to the Closing be, duly executed
                                            and delivered by the Buyer and (assuming the due authorization, execution and delivery by
                                            the other parties thereto) each of the Buyer Documents constitutes (or, when executed, will
                                            constitute) a legal, valid and binding obligation of the Buyer, enforceable against the Buyer
                                            in accordance with its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify"><U>Issued Shares/Warrants</U>. The Issued
                                            Shares/Warrants, shall represent at the Closing 19.99% of the issued and outstanding capital
                                            stock of Buyer.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify"><U>Capital Structure</U>. Buyer capital structure
                                            materially conforms to the capital structure described in the Buyer Reports. Except as disclosed
                                            in the Buyer Reports (as defined below), there are no outstanding bonds, debentures, notes
                                            or other indebtedness or other securities of Buyer having the right to vote (or convertible
                                            into, or exchangeable for, securities having the right to vote) on any matters of which stockholders
                                            of Buyer are entitled to vote on. Except as disclosed in Buyer Reports and as set forth herein,
                                            there are no outstanding securities, options, warrants, calls, rights, commitments, agreements,
                                            arrangements or undertakings of any kind to which Buyer is a party or by which it is bound
                                            obligating Buyer to issue, deliver or sell, or cause to be issued, delivered or sold, additional
                                            common stock of Buyer or other equity or voting securities of Buyer or obligating Buyer to
                                            issue, grant, extend or enter into any such security, option, warrant, call, right, commitment,
                                            agreement, arrangement or undertaking. There are no outstanding contractual obligations,
                                            commitments, understandings or arrangements of Buyer to repurchase, redeem or otherwise acquire
                                            or make any payment in respect of any ordinary shares of Buyer or any other securities of
                                            Buyer. There are no agreements or arrangements pursuant to which Buyer is or could be required
                                            to register Buyer&rsquo; ordinary shares or other securities under the Securities Act or
                                            other agreements or arrangements with or among any holders of Buyer or with respect to any
                                            securities of Buyer.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.5</TD><TD STYLE="text-align: justify"><U>Reports</U>. The Buyer has filed all forms,
                                            reports and documents with the SEC that have been required to be filed by it under applicable
                                            laws prior to the date hereof&thinsp;(all such forms, reports and documents, together with
                                            all documents filed or furnished on a voluntary basis and all exhibits and schedules thereto,
                                            the &ldquo;<B>Buyer Reports</B>&rdquo;). As of its filing date (or, if amended or superseded
                                            by a filing prior to the date of this Agreement, on the date of such amended or superseded
                                            filing), (i) each Buyer Report complied as to form in all material respects with the applicable
                                            requirements of the Securities Act, the Exchange Act, and/or the Sarbanes-Oxley Act, as the
                                            case may be, each as in effect on the date such Buyer Report was filed, and (ii) each Buyer
                                            Report did not contain any untrue statement of a material fact or omit to state any material
                                            fact necessary in order to make the statements made therein, in the light of the circumstances
                                            under which they were made, not misleading. To the knowledge of Buyer, none of the Buyer
                                            Reports is the subject of ongoing SEC review or investigation. The financial statements of
                                            Buyer included in the Buyer Reports comply in all material respects with the applicable accounting
                                            requirements and the rules and regulations of the SEC with respect thereto as in effect at
                                            the time of filing. The financial statements included in the Buyer Reports have been prepared
                                            in accordance with International Financial Reporting Standards (&ldquo;<B>IFRS</B>&rdquo;),
                                            and fairly represent the financial position of Buyer and as of and for the dates thereof
                                            and the results of operations and cash flows for the periods then ended, subject, in the
                                            case of unaudited statements, to normal, year-end audit adjustments and the omission of certain
                                            footnotes. Except as set forth in the Buyer Reports, Buyer has no liabilities or obligations
                                            of any nature (whether accrued, absolute, contingent or otherwise) required by IFRS to be
                                            set forth on a balance sheet of Buyer or in the notes thereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.6</TD><TD STYLE="text-align: justify"><U>Litigation</U>. There is no litigation,
                                            suit, action, arbitration, inquiry, investigation or proceeding pending or, to the knowledge
                                            of Buyer, threatened, before any court, agency, or other governmental body against Buyer
                                            (or any corporation or entity affiliated with Buyer) which seeks to enjoin or prohibit or
                                            otherwise prevent the transactions contemplated hereby.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.7</TD><TD STYLE="text-align: justify"><U>Experience; Receipt of Information</U>.
                                            Buyer has such knowledge and experience in financial and business matters in general and
                                            in the business of the Seller, in particular, and is capable of evaluating the merits and
                                            risks relating to the acquisition of the Acquired Assets. The Buyer has been furnished by
                                            the Seller with documents and information regarding the Acquired Assets, and has been afforded
                                            the opportunity to ask questions of and receive answers from duly authorized officers or
                                            other representatives of the Seller concerning the Acquired Assets.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.8</TD><TD STYLE="text-align: justify"><U>Consents</U>. No consent, waiver, approval,
                                            order, permit or authorization of, or declaration or filing with, or notification to, any
                                            person or governmental body is required on the part of the Buyer in connection with the execution
                                            and delivery of any of the Buyer Documents or the compliance by the Buyer with any of the
                                            provisions thereof, except with the SEC and as required for the registration of the Issued
                                            Shared and/or Warrant Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.9</TD><TD STYLE="text-align: justify"><U>Disclosure of Information</U>. The Buyer
                                            has had an opportunity to discuss the Seller&rsquo;s business, operations, properties, prospects,
                                            technology, plans, management, financial affairs and the terms and conditions of the offering
                                            of the Acquired Assets with the Seller&rsquo;s management and has had an opportunity to review
                                            the Acquired Assets and the business of the Seller.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.10</TD><TD STYLE="text-align: justify"><U>Condition of the Acquired Assets. </U>Buyer
                                            have made all inspections and investigations of the Acquired Assets deemed necessary or desirable
                                            by Buyer. Buyer acknowledges and agrees that (a) it is purchasing the Acquired Assets based
                                            on the results of its inspections and investigations, and not on any representation or warranty
                                            of Seller not expressly set forth in this Agreement and (b) except as otherwise set forth
                                            in this Agreement, the Acquired Assets are sold &ldquo;as is, where is&rdquo; and it accepts
                                            the Acquired Assets in the condition they are in and at the place where they are located
                                            on the Closing. In light of these inspections and investigations and the representations
                                            and warranties expressly made to Buyer by Seller herein, Buyer is relinquishing any right
                                            to any claim based on any representations and warranties other than those expressly set forth
                                            in this Agreement and the certificates and other documents delivered pursuant hereto or thereto.
                                            Any claims Buyer may have for breach of representation or warranty shall be based solely
                                            on the representations and warranties of Seller set forth in this Agreement and the certificates
                                            and other documents delivered pursuant hereto or thereto. BUYER ACKNOWLEDGES AND AGREES THAT,
                                            EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 4, NEITHER SELLER, ITS AFFILIATES,
                                            NOR ANY OTHER PERSON HAS MADE OR MAKES ANY OTHER REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,
                                            EITHER IN FACT OR BY OPERATION OF LAW, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY,
                                            OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR WARRANTY AS TO QUALITY, OR ANY WARRANTY AS
                                            TO THE VALIDITY OR ENFORCEABILITY OF ANY TRANSFERRED PATENT RIGHTS OR THE NON-INFRINGEMENT
                                            OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.</B></TD><TD STYLE="text-align: justify"><B>POST-CLOSING COVENANTS</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify"><U>Transfer and obtaining of Registrations</U>.
                                            The parties shall diligently transfer to Buyer, at Buyer&rsquo;s sole cost and expense, all
                                            registrations concerning the Acquired Assets. In this respect Seller shall provide such information,
                                            documents, powers of attorney, and shall provide such instructions and take such actions,
                                            etc., all as reasonably required by Buyer and necessary to effect (i) the transfer of the
                                            Acquired Assets and the registrations thereof; and (ii) the registration of such transfer
                                            of the Acquired Assets and the registrations with the applicable authorities and institutions
                                            worldwide in which the Acquired Assets are currently registered in, including but not limited
                                            to transfer of the registrations of the Transferred IP Rights with the applicable patent
                                            and trademark authorities and institutions, and subject to compliance and fulfillment of
                                            Buyer obligations for such actions, including signing any required documents and instruments
                                            and providing any information, certification or documents required by Seller and/or the respective
                                            authorities, institutions and registrars for such purpose. From time to time, after the Closing
                                            Date and during a period of 18 months from the Closing Date, the Seller shall at the reasonable
                                            request (and with the reasonable cooperation) and at the expense of the Buyer, execute and
                                            deliver, or use its best efforts to cause to be executed and delivered, all such other and
                                            further instruments of sale, assignment, assumption, transfer and conveyance and other documents
                                            and instruments, as may be reasonably required or desirable to confirm or record the Buyer&rsquo;s
                                            rights in the Acquired Assets and take all such other and further action, as the Buyer may
                                            reasonably request, in order to vest or perfect the Buyer&rsquo;s right, title and interest
                                            in and to the Acquired Assets.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.2</TD><TD STYLE="text-align: justify"><U>Transferred IP Rights Maintenance</U>.
                                            Buyer shall be responsible at its own costs, for the preparation, filing, prosecution, protection
                                            and maintenance of the Assigned Patent Rights in all territories they are currently registered.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.3</TD><TD STYLE="text-align: justify"><U>Insurance</U>. Buyer shall maintain insurance
                                            with respect to its activities under this Agreement regarding the Acquires Assets in such
                                            amount as such party customarily maintains with respect to similar activities for its other
                                            products, but not less than such amount as is reasonable and customary in the medical device
                                            industry. Each insurance policy shall name as additional insureds Seller and their, directors,
                                            officers, agents and employees and be placed with a reputable insurer with a minimum AM Best
                                            rating of A- VII, or S&amp;P A, or better.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.4</TD><TD STYLE="text-align: justify"><U>Confidentiality and Nondisclosure</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">6.4.1</TD><TD STYLE="text-align: justify">The Seller and the Buyer agree that
                                            all information relating to the Acquired Assets, including but not limited to the following,
                                            shall be deemed confidential information: business strategies, technology plans, financial
                                            conditions, business plans, marketing strategies and plans, data, business records, customer
                                            lists, and any and all information concerning the Acquired Assets that would be deemed confidential,
                                            a trade secret, a customer list, or other form of proprietary information of the Seller (collectively
                                            &ldquo;<B>Confidential Information</B>&rdquo;). The Seller and the Buyer hereby agree, that
                                            up until the Closing Date all of the Confidential Information shall be solely owned by the
                                            Seller, and that immediately following the Closing Date all of the Confidential Information
                                            shall be solely owned by the Buyer.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">6.4.2</TD><TD STYLE="text-align: justify">The Seller and the Buyer hereby expressly
                                            agree to maintain such Confidential Information of the other party and not to disclose any
                                            Confidential Information owned by the other party to any third party. The Seller or Buyer
                                            may, however, disclose such Confidential Information if required by law or court order, provided
                                            that the disclosing party gives the other party prior written notice and makes good faith
                                            best efforts to obtain confidential treatment for such Confidential Information.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 42.55pt">6.4.3</TD><TD STYLE="text-align: justify">Notwithstanding the above, Confidential
                                            Information shall not include any information relating to the Excluded Assets, which shall
                                            at all times remain the sole property of the Seller and be deemed as Confidential Information
                                            of the Seller.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.5</TD><TD STYLE="text-align: justify"><U>Joint PR</U>. Subject to Section 6.2 above,
                                            the parties may jointly issue a PR in a form and language as mutually agreed in writing between
                                            the parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -21.25pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>7.</B></TD><TD STYLE="text-align: justify"><B>SURVIVAL AND INDEMNIFICATION</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify"><U>Survival of Representations and Warranties</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The representations and
warranties of Seller and Buyer and the covenants and agreements that by their nature are required to be performed at or prior to the
Closing, in each case contained in this Agreement, shall survive the Closing and remain in full force and effect until the date that
is twelve&nbsp;(12) months from the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) All of the covenants and
agreements contained in this Agreement that by their nature are required to be performed after the Closing shall survive the Closing
until fully performed or fulfilled, unless and only to the extent that non-compliance with such covenants or agreements is waived by
the Party entitled to such performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.2</TD><TD STYLE="text-align: justify"><U>Indemnified Losses</U>.
                                            For the purpose of this Section 7.2, and when used elsewhere in this Agreement, the term
                                            &ldquo;<B>Loss</B>&rdquo; shall mean and include, any and all direct liability, loss, damage,
                                            claim, expense, cost, fine, fee, penalty, obligation or injury including, without limitation,
                                            those resulting from any and all actions, suits, proceedings, demands, assessments, judgments,
                                            award or arbitration, together with reasonable costs and actual expenses incurred, including
                                            the reasonable attorneys&rsquo; fees and other legal costs and direct expenses relating thereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -58.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2.1</TD><TD STYLE="text-align: justify"><U>Indemnification by Seller</U>. Subject
                                            to the provisions of this Section 7, Seller agrees, from and after the Closing Date, to defend,
                                            indemnify and hold harmless the Buyer and any director, officer, employee, or attorney thereof,
                                            from and against any Loss actually suffered or incurred by any Buyer Indemnified Party to
                                            the extent actually arising from or relating to any: (i) breach of the Seller&rsquo;s representations
                                            and warranties as set forth in Section 4 above and/or Sellers&rsquo;s covenants under the
                                            Agreement; (ii) any Excluded Assets; or (iii) any Third Party) claim related to the Excluded
                                            Assets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -58.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2.2</TD><TD STYLE="text-align: justify"><U>Indemnification by Buyer</U>. Subject
                                            to the provisions of this Section 7, Buyer agrees, from and after the Closing Date, to defend,
                                            indemnify and hold harmless the Seller and any director, officer, employee, or attorney thereof,
                                            from and against any Loss actually suffered or incurred by such Seller Indemnified Party
                                            to the extent arising from or relating to any: (i) breach of the Buyer&rsquo;s representations
                                            and warranties as set forth in Section 5 above and/or Buyer&rsquo;s covenants under the Agreement;
                                            (ii) use, ownership, possession, operation, sale, lease, service or other exploitation of
                                            any of the Acquired Assets from and after the Closing; or (iii) any Assumed Liability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Any person providing
indemnification pursuant to the provisions of this 7 is hereinafter referred to as an &ldquo;<B>Indemnifying Party</B>&rdquo; and any
person entitled to be indemnified pursuant to the provisions of this <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section
7 is hereinafter referred to as an &ldquo;<B>Indemnified Party</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.3</TD><TD STYLE="text-align: justify">The right for indemnification provided under
                                            this Agreement is the parties&rsquo; exclusive remedy for any breach of the representations,
                                            warranties, covenants, agreements, and obligations in this Agreement. Any claim for indemnification
                                            under this Agreement, may only be asserted and filed by the parties within the Survival Period,
                                            and with respect to either of the parties&rsquo; covenants and agreements contained in this
                                            Agreement, that by their nature are required to be performed after the Closing and/or the
                                            Survival Period, shall survive the Closing and the Survival Period until fully performed
                                            or fulfilled.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.4</TD><TD STYLE="text-align: justify"><U>Procedures for Third Party Claims</U>.
                                            In the case of any claim of a third party that may reasonably give rise to Losses, for which
                                            an Indemnifying Party may be liable for indemnification under this Section 7 (a &ldquo;<B>Third
                                            Party Claim</B>&rdquo;), an Indemnified Party shall give prompt written notice to the Indemnifying
                                            Party of any claim or demand which such Indemnified Party has knowledge and as to which it
                                            may request indemnification hereunder. Each claim notice shall (A)(1)&nbsp;specify in reasonable
                                            detail all relevant facts, conditions and events, and (2)&nbsp;identify the specific provisions
                                            of this Agreement which give rise to such indemnification right; and (B)&nbsp;include a good-faith
                                            estimate of the amount of Losses for which the Indemnified Party is seeking indemnification
                                            from the Indemnifying Party. The Indemnifying Party shall have the right to defend and to
                                            direct the defense against any such Third Party Claim, in its name or in the name of the
                                            Indemnified Party, as the case may be, at the expense of the Indemnifying Party, and with
                                            counsel selected by the Indemnifying Party unless: (a) such Third Party Claim seeks an order,
                                            injunction or other equitable relief against the Indemnified Party, or (b) the Indemnified
                                            Party shall have reasonably concluded that (i) there is a conflict of interest between the
                                            Indemnified Party and the Indemnifying Party in the conduct of the defense of such Third
                                            Party Claim, or (ii) the Indemnified Party has one or more defenses not available to the
                                            Indemnifying Party. Notwithstanding anything in this Agreement to the contrary, the Indemnified
                                            Party shall, at the expense of the Indemnifying Party, cooperate with the Indemnifying Party,
                                            and keep the Indemnifying Party fully informed, in the defense of such Third Party Claim.
                                            The Indemnified Party shall have the right to participate in the defense of any Third Party
                                            Claim with counsel employed at its own expense; provided, however, that, in the case of any
                                            Third Party Claim described in clause (a) or (b) of the second preceding sentence or as to
                                            which the Indemnifying Party shall not in fact have employed counsel to assume the defense
                                            of such Third Party Claim, the reasonable fees and disbursements of such counsel shall be
                                            at the expense of the Indemnifying Party. The Indemnifying Party shall have no indemnification
                                            obligations with respect to any Third Party Claim which shall be settled by the Indemnified
                                            Party without the prior written consent of the Indemnifying Party, which consent shall not
                                            be unreasonably withheld, delayed or conditioned.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.5</TD><TD STYLE="text-align: justify"><U>Procedures for Inter-Party Claims</U>.
                                            In the event that an Indemnified Party determines that it has a claim for Losses against
                                            an Indemnifying Party hereunder (other than as a result of a Third Party Claim), the Indemnified
                                            Party shall give prompt written notice thereof to the Indemnifying Party, specifying the
                                            amount of such claim and any relevant facts and circumstances relating thereto. The Indemnified
                                            Party shall provide the Indemnifying Party with reasonable access to its books and records
                                            for the purpose of allowing the Indemnifying Party a reasonable opportunity to verify any
                                            such claim for Losses. The Indemnified Party and the Indemnifying Party shall negotiate in
                                            good faith regarding the resolution of any disputed claims for Losses. In the event of disagreement
                                            on the Losses, the Indemnified Party shall be entitled to submit a claim to the authorized
                                            court in Israel against the Indemnifying Party and the cost of such proceedings (including
                                            costs of investigation and reasonable attorney fees and disbursements) shall be awarded to
                                            the prevailing party.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.6</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in
                                            this Agreement, the total aggregate liability of any Indemnifying Party to pay indemnification
                                            amounts, is expressly limited as set forth in each and all of the provisions below: (i)&nbsp;
                                            where the Losses incurred by the Indemnified Party exceeds USD 100,000 (the&nbsp;&ldquo;<B>Deductible</B>&rdquo;),
                                            at which time only such Losses in excess of the Deductible will be subject to indemnification
                                            hereunder; and (ii)&nbsp;Seller&rsquo;s or Buyer's aggregate Liability for indemnification
                                            pursuant to this Section 7, unless arising in connection with fraud or Third Party Claims,
                                            will not exceed fifteen percent&nbsp;(15%) of the value of the Transaction Consideration
                                            at the Closing date.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.7</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary contained
                                            herein, neither party shall be liable for any (i) special, punitive, exemplary, incidental,
                                            consequential or indirect damages, (ii) lost profits or lost business, loss of enterprise
                                            value, diminution in value of any business, damage to reputation or loss of goodwill; or
                                            (iii) damages calculated based on a multiple of profits, revenue or any other financial metric,
                                            in each case, whether based on contract, tort, strict liability, other laws or otherwise,
                                            and whether or not arising from any other party&rsquo;s sole, joint or concurrent negligence,
                                            strict liability or other fault.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.8</TD><TD STYLE="text-align: justify"><U>Sole Remedy; Waiver</U>. Each Party acknowledges
                                            and agrees that the remedies provided for in this Agreement shall be its sole and exclusive
                                            remedy with respect to the subject matter of this Agreement. In furtherance of the foregoing,
                                            each of the Parties hereby waives, to the fullest extent permitted by applicable Law, any
                                            and all other rights, claims and causes of action (including rights of contributions, if
                                            any) known or unknown, foreseen or unforeseen, which exist or may arise in the future, that
                                            it may have against Seller, or Buyer or any of their Indemnified Parties, as the case may
                                            be, arising under or based upon any applicable Law, except that nothing herein shall limit
                                            the liability of either Party for fraud.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD STYLE="text-align: justify"><B>TERMINATION</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.1</TD><TD STYLE="text-align: justify">This Agreement may be terminated and the transactions
                                            contemplated hereby abandoned at any time prior to the Closing: (i) by mutual written agreement
                                            of Seller and Buyer; (ii) by either party &ndash; in the event that any of the Conditions
                                            to obligations of each Party to effect the Agreement, as set forth in Section 3.3 above,
                                            has not been met by the Closing Date; or (iii) by Buyer or Seller - in the event that any
                                            of the Conditions precedent to the obligations of each Buyer or Seller, as set forth in Section
                                            3.4 or 3.5 above, has not been met by the Closing Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.2</TD><TD STYLE="text-align: justify">In the event of termination of this Agreement
                                            as provided above, this Agreement shall be of no further force and effect and there shall
                                            be no further obligations on the part of Buyer or Seller or their respective officers, directors,
                                            shareholders, affiliates or representatives; provided, however, that notwithstanding anything
                                            herein to the contrary, Section 6.2 (Confidentiality), this Section 8.2 and Section 9 (Miscellaneous),
                                            will remain in full force and effect and survive any termination of this Agreement; and nothing
                                            herein will relieve any party hereto from liability arising out of or resulting from any
                                            fraud or intentional breach occurring prior to such termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>9.</B></TD><TD STYLE="text-align: justify"><B><U>MISCELLANEOUS</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U>. This Agreement (including
                                            the schedules hereto) is intended as, a complete statement of all of the terms and the arrangements
                                            between the parties hereto with respect to the matters provided for herein or therein, and
                                            supersedes any and all previous agreements and understandings, written and oral, between
                                            the parties hereto with respect to those matters, including the Binding Term Sheet for the
                                            Sale of Patent Portfolio &amp; Trademarks executed between the parties dated November 26,
                                            2025.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.2</TD><TD STYLE="text-align: justify"><U>Further Assurances</U>. Each party agrees
                                            that it will execute and deliver, or cause to be executed and delivered, on or after the
                                            date of this Agreement and after the Closing, all such other instruments and will take all
                                            reasonable actions as may be necessary to transfer and convey the Acquired Assets to Buyer,
                                            on the terms herein contained, and to consummate the transactions herein contained to effectuate
                                            the provisions and purposes hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.3</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. This Agreement shall
                                            be exclusively governed by and construed in accordance with the laws of the State of Israel,
                                            without giving effect to principles of conflicts of law. The courts of Israel (in either
                                            Tel-Aviv or the city of Haifa) will have exclusive jurisdiction over all claims arising out
                                            of or relating to this Agreement and any ancillary document related thereto, and each party
                                            hereby consents and submits to such exclusive jurisdiction.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.4</TD><TD STYLE="text-align: justify"><U>No Waiver</U>. No failure or delay by either
                                            party in exercising any right, power or privilege hereunder shall operate as a waiver thereof,
                                            nor shall any single or partial exercise thereof preclude any other, or further, exercise
                                            thereof or the exercise of any other right, power or privilege.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.5</TD><TD STYLE="text-align: justify"><U>Expenses</U>. Each of the parties hereto
                                            shall bear its own expenses (including, without limitation, fees and disbursements of its
                                            counsel, accountants and other experts), incurred by it in connection with the preparation,
                                            negotiation, execution, delivery and performance of this Agreement, each of the other documents
                                            and instruments executed in connection with or contemplated by this Agreement and the consummation
                                            of the transactions contemplated hereby and thereby; provided, however, that Buyer shall
                                            be responsible for all fees and expenses associated with the transfer of title to the Acquired
                                            Assets from Seller to Buyer. If the Seller actually pays any of those amounts on behalf of
                                            Buyer than Buyer shall indemnify Seller for those expenses.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.6</TD><TD STYLE="text-align: justify"><U>Notices</U>. All notices, requests, permissions,
                                            waivers, and other communications hereunder shall be in writing and shall be deemed to have
                                            been duly given, (a) five business days following sending by registered or certified mail,
                                            postage prepaid, (b) one business day after it was sent, if sent by electronic mail or other
                                            forms of electronic messaging; <I>provided </I>that the such electronic transmission is confirmed
                                            by telephone or by electronic means, (c) when delivered, if delivered personally to the intended
                                            recipient, and (d) one business day following sending by overnight delivery via a national
                                            courier service, and in each case, addressed to a party at the following address for such
                                            party:</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt">If to the Seller, to:</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 58%"><P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>XYLO Technologies Ltd.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">10 Hanechoshet St., Tel Aviv
    &ndash; Yafo 6971072, Israel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">e-mail:&nbsp;&nbsp;&nbsp;__________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">With a copy to (which shall not be deemed as due notice):</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Primes &amp; Co. &ndash;
    Law Firm</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">16 Derech Hayam, Haifa 34741,
    Israel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adv.
    Meytal Katz, Partner</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">e-mail:&nbsp;&nbsp;&nbsp;meytal@pgs-law.co.il</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">If to the Buyer, to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SciSparc Ltd.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">20 Raoul Wallenberg St., Tel
    Aviv &ndash; Yaffo 6971904, Israel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oz
    Adler</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">e-mail:&nbsp;&nbsp;&nbsp;Oz@scisparc.com</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">With a copy to (which shall not be deemed as due notice):</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Meitar | Law Offices</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Address: 16 Abba Hillel Road,
    Ramat Gan, 5250608, Israel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Attn:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.
    Shachar Hadar, Partner</P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">e-mail:&nbsp;&nbsp;&nbsp;Shacharh@metiar.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">or to such other address(es) as shall
be furnished in writing by any such party to each of the other parties hereto in accordance with the provisions of this Section 9.6.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.7</TD><TD STYLE="text-align: justify"><U>Binding Effect</U>. This Agreement shall
                                            be binding upon and inure to the benefit of the parties and their respective successors and
                                            assigns.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.8</TD><TD STYLE="text-align: justify"><U>Amendments</U>. This Agreement may be amended,
                                            supplemented or modified, and any provision hereof may be waived, only pursuant to a written
                                            instrument making specific reference to this Agreement signed by each of the parties hereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.9</TD><TD STYLE="text-align: justify"><U>No Presumption; Waiver</U>. Each of the
                                            parties agrees, represents and acknowledges that it was duly represented in this Agreement,
                                            its drafting, negotiations and in the underlying transaction, with such legal counsel of
                                            its choice, and that neither party is relying on the representation and legal counsel or
                                            advice of the other party.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.10</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be
                                            executed in any number of counterparts, each of which shall be deemed an original, but all
                                            of which together shall constitute one and the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Intentionally left blank
&ndash; next page is the signature page]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page to the
Asset Purchase Agreement, between XYLO &amp; SciSparc, dated January 8,2026]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have executed this Agreement as of the APA Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Xylo Technologies Ltd.</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ SciSparc Ltd.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>XYLO TECHNOLOGIES
    LTD.</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(Seller)</P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SCISPARC LTD.</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(Buyer)</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">By its Authorized Signatory</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">By its Authorized Signatory</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 35%">Eli Yoresh</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 35%">Oz Adler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea027253602ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE A TREASURY OF PATENTS FOR THE ENDOSCOPE MARKET- ENTERING MULTI-BILLION DOLLAR OPPORTUNITY."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 74px; width: 74px"></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SciSparc
Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>SciSparc
intends to commence commercialization of these patented technologies immediately following the transaction closing</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TEL
AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (&ldquo;Company&rdquo; or&nbsp;&ldquo;SciSparc&rdquo;),
a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced
today the signing of a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative
endoscopic systems and medical cameras, including the MUSE&trade; system, from Xylo Technologies Ltd. (&ldquo;Xylo&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MUSE&trade; system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure
to treat gastroesophageal reflux disease (&ldquo;GERD&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
intends to commence commercialization of these patented technologies immediately following the transaction closing, building on the established
foundation to drive rapid market penetration and revenue generation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building
on Xylo&rsquo;s successful commercialization in Greater China through licensing and distribution agreement with a Shanghai-based medical instruments
company in 2019, under which Xylo received $3 million up front, SciSparc seeks to replicate this proven model across high-growth territories,
such as North America, Europe and Latin America, by pursuing similar exclusive partnerships with leading regional distributors to accelerate
global commercialization and unlock substantial revenue streams.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the definitive agreement, SciSparc will acquire the complete portfolio of patents, trademarks, know-how, and related intellectual
property rights, mainly associated with the MUSE&trade; system, from Xylo. In consideration for the acquired assets, SciSparc will issue
to Xylo, upon the closing of the transaction (the &ldquo;Closing&rdquo;), an amount of ordinary shares of the Company, which shall represent,
as of the Closing date, which is set on March 8, 2026, 19.99% of the issued and outstanding share capital of SciSparc (the &ldquo;Issued
Shares&rdquo;). SciSparc may elect, at its sole discretion, to issue, in lieu (in whole or in part) the Issued Shares, pre-funded warrants
to purchase ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction remains subject to customary closing conditions, including any required regulatory approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a May 2025 market research report by MarkNtel Advisors, the global&nbsp;GERD
device market was valued&nbsp;at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a
compound annual growth rate (CAGR) of 3.24% from 2025 to 2030.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
press release does not constitute an offer of securities for sale in the United States. The securities referred to herein have not been
registered under the United States Securities Act of 1933, as amended (the&nbsp;&ldquo;U.S. Securities Act&rdquo;), and such securities
may not be offered or sold within the United States absent registration or an applicable exemption from the registration requirements
of the U.S. Securities Act.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
SciSparc Ltd. (Nasdaq: SPRC):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc&rsquo;s
focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the
Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs
based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer&rsquo;s disease and
agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release contains forward-looking statements within the meaning
of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws.
For example, SciSparc uses forward-looking statements when it discusses: the expected acquisition of a portfolio of patents, trademarks
and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE&nbsp;<SUP>TM</SUP>&nbsp;system
from Xylo; the consideration for the acquired assets to be paid to Xylo at Closing; the Company&rsquo;s plans to replicate Xylo&rsquo;s
licensing and distribution model from Greater China to other territories, such as North America, Europe and Latin America; the Company&rsquo;s
plans to pursue exclusive partnerships with leading regional distributors to accelerate commercialization and unlock substantial revenue
streams; the Closing Date, the Company&rsquo;s intention to commercialize these patented technologies and the timing thereof and the expected
value and growth of the global GERD device market. The acquisition of the intellectual property assets described in this press release
is subject to customary closing conditions, including any required regulatory approvals. Because such statements deal with future events
and are based on SciSparc&rsquo;s current expectations, they are subject to various risks and uncertainties and actual results, performance
or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the
heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and
in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention
or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Contact:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR@scisparc.com<BR>
Tel: +972-3-6167055</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* $D# 2(  A$! Q$!_\0
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F"T,L]S';6EN(HS-</NN;@D# 9S(2QRI(( W JM;%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
